title: Repeated intravitreal triamcinolone injections in Behçet disease that is resistant to conventional therapy: one-year results.
abstract: OBJECTIVE
  To determine whether repeated intravitreal triamcinolone (IVTA) injections in patients with Behçet disease that is resistant to conventional therapy will prevent recurrences of uveitis.
  
  
  METHODS
  Prospective preliminary clinical trial.
  
  
  METHODS
  Nine eyes of five patients with Behçet disease with sight-threatening uveitis that was resistant to conventional therapy received repeated IVTA injections. Each patient was examined monthly, and IVTA was given when the TA particles that remained in the vitreous were judged to be gone before the next visit.
  
  
  RESULTS
  Repeated IVTA completely prevented the recurrence of uveitis in eight eyes, and the one eye that had an attack experienced the uveitis when the TA particles disappeared quicker than expected. It was possible to stop systemic corticosteroid and/or immunosuppressive agents within 1 year after IVTA in three patients.
  
  
  CONCLUSIONS
  These results indicate that repeated IVTA will prevent the recurrence of uveitis in patients with Behçet disease with frequent ocular attacks that is resistant to conventional therapy.
authors.affiliation: Department of Ophthalmology, Osaka University Medical School E7, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. nohguro@ophthal.med.osaka-u.ac.jp
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Ohguro
authors.forename: Emiko
authors.initials: E
authors.lastname: Yamanaka
authors.forename: Yasumasa
authors.initials: Y
authors.lastname: Otori
authors.forename: Yoshitsugu
authors.initials: Y
authors.lastname: Saishin
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Tano
mesh_terms: D000328:Adult; D001528:Behcet Syndrome / Q000188:drug therapy*; D004351:Drug Resistance; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007267:Injections; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D019233:Retreatment; D055502:Secondary Prevention; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D014822:Vitreous Body
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D014222:Triamcinolone Acetonide